Search

760 Result(s)
Sort by

The status of schizophrenia care

The status of schizophrenia care

A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Giving Life a Chance

Giving Life a Chance

The Angels initiative honours stroke units and the everyday heroes making a difference for stroke patients
We support non-linear career paths.

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Kicking off 2024 with five new R&D partnerships

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Martin Stefanic

Martin Stefanic

Learn how Patient Safety is at the cutting edge of innovation.
Scleroderma Life Hacks

Scleroderma Life Hacks

Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Spesolimab Phase II data

Spesolimab Phase II data

New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
The Goals to Improve Living with GPP

The Goals to Improve Living with GPP

An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Embracing diversity in clinical trials

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Eugene Zalmover

Eugene Zalmover

Learn how Eugene’s work paved the way for digital innovation in Patient Safety.
Rafael Sani Simoes

Rafael Sani Simoes

Learn how Rafael’s role in Patient Safety enables him to make a difference.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF